Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness

BACKGROUND: The epidermal growth factor receptor (EGFR) is a therapeutic target for patients with non-small cell lung cancer (NSCLC). Cetuximab is an anti-EGFR monoclonal antibody that inhibits EGFR signaling and proliferation of colorectal cancer and head and neck cancers. Since only few NSCLC pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Yonago Acta Med
Main Authors: Miyake, Naomi, Chikumi, Hiroki, Yamaguchi, Kosuke, Takata, Miyako, Takata, Miki, Okada, Kensaku, Kitaura, Tsuyoshi, Nakamoto, Masaki, Yamasaki, Akira
Formato: Artigo
Idioma:Inglês
Publicado em: Tottori University Faculty of Medicine 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437414/
https://ncbi.nlm.nih.gov/pubmed/30962749
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados